GlassScriptPhysician profile
Christian J Rhea
NPI 1982668976
$81,071.79
in general payments reported to CMS, 2019-2025
40 companies · $4,314 in 2025
The $4,314 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $15K · 2021: $7,132 · 2022: $5,895 · 2023: $4,202 · 2024: $4,828 · 2025: $4,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,171.32 |
| Education | $172.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58,843.96 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $8,384.02 | 2019-2025 | |
| Ucb, INC. | $2,261.88 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $2,095.31 | 2019-2025 | |
| Janssen Biotech, INC. | $1,603.92 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,042.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,019.80 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $851.36 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $553.74 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $524.07 | 2023-2025 | |
| Horizon Therapeutics Plc | $419.66 | 2020-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $418.61 | 2020-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $393.34 | 2019-2025 | Orencia |
| Sobi, INC | $315.22 | 2020-2025 | |
| Aurinia Pharma U.S., INC. | $266.35 | 2021-2025 | Lupkynis |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.85 | 2019-2024 | Cyltezo, Ofev |
| Mallinckrodt Hospital Products INC. | $225.22 | 2022-2025 | Acthar |
| Organon LLC | $207.59 | 2023-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $194.42 | 2020-2025 | Tymlos |
| Genzyme Corporation | $173.67 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $143.72 | 2023 | Tremfya |
| Genentech USA, INC. | $127.22 | 2019-2025 | Actemra |
| Pacira Therapeutics, INC. | $102.94 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $94.31 | 2023-2025 | Strensiq, Ultomiris |
| Teva Pharmaceuticals USA, INC. | $73.58 | 2023-2024 | Simlandi, Truxima |
| Pacira Pharmaceuticals Incorporated | $62.60 | 2023-2024 | Iovera, Zilretta |
| Sandoz INC. | $54.96 | 2023-2025 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $47.82 | 2023 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $38.18 | 2024 | Arcalyst |
| Tersera Therapeutics LLC | $37.83 | 2025 | Quzyttir |
| Celltrion USA INC. | $37.35 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals, LTD. | $35.83 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $31.75 | 2024 | Onpattro |
| Tonix Medicines, INC. | $27.40 | 2025 | Tonmya |
| Celgene Corporation | $24.33 | 2019 | |
| Depuy Synthes Sales INC. | $23.24 | 2025 | Monovisc, Orthovisc |
| Hikma Pharmaceuticals USA | $23.03 | 2022 | |
| Zimmer Biomet Holdings, INC. | $19.83 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Mylan Institutional INC. | $13.92 | 2023 | Hulio |
| Sanofi-Aventis U.S. LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Rhea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.